Form 4: Processa Pharmaceuticals Insider Buys Shares

David Young, Director and Officer at Processa Pharmaceuticals, acquired 2,531 shares of common stock on June 30, 2026, at a price of $1.93 per share.

Summary

• David Young, who holds the positions of Director and President of Research & Development at Processa Pharmaceuticals, Inc., purchased 2,531 shares of common stock.
• The transaction occurred on June 30, 2026, with shares acquired at a price of $1.93 each.
• Following this acquisition, Mr. Young's beneficial ownership of common stock totals 21,729 shares, held directly.
• Additional holdings are reported indirectly through the Young-Plaisance Revocable Trust (1,242 shares), Family Entities (432 shares), and CorLyst, LLC (1,009 shares).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing due to the insider purchase by a director and officer, signaling confidence in the company.

Positives

• Insider purchase of company stock by a key executive and director, indicating confidence in the company's future.
• Acquisition of 2,531 shares at a price of $1.93 per share.

Future Outlook

No specific forward-looking statements or guidance are present in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider purchases, particularly by directors and officers, are often interpreted by the market as a positive signal of management's belief in the company's intrinsic value and future prospects.

Stakeholder Impact

• Shareholders may view this insider purchase positively, potentially leading to increased confidence in the company's management and future performance.

Key Dates

Keywords

Processa Pharmaceuticals, PCSA, Form 4, Insider Trading, Stock Acquisition, Beneficial Ownership, David Young